Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionCastle Biosciences Inc. Common Stock (CSTL)
Fair value (2 models)
Not available
ACCE price target
$35.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Price used: $33.08 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
55
out of 100
Analysts
100% buy
9 covering
1-year return
+36.8%
Dividend yield
0.00%
Castle Biosciences Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Castle Biosciences sells genomic and molecular diagnostic tests, including the DecisionDx family for melanoma, uveal melanoma, and Barrett's esophagus, plus its MyPath and TissueCypher tests, which are ordered by dermatologists, oncologists, and gastroenterologists. The core advantage is reimbursement: the company has built a base of tests with payer coverage and a 77.3% gross margin, which tells you the economics of each result are strong once volume is there. Revenue grew 20.1% over the last year, and the near-term story rests on test volume and reimbursement expansion across these franchises. Operating margin is still slightly negative at -3.0% and ROE is -4.2%, so this is a company where profitability depends on operating leverage arriving as volume scales. At a $1.0B market cap with no index membership and a composite score of 55/100, the name is worth a deeper look mainly to test whether the gross margin and 20% growth translate into a clear path to positive operating margin.